CXCR4 Chemokine Antagonist Scores a First FDA Approval for WHIM Syndrome

The FDA has approved X4 Pharmaceuticals’ mavorixafor (Xolremdi) for a rare immune deficiency disorder that leads to recurrent, life-threatening infections. Mavorixafor, a small-molecule CXC chemokine receptor 4 (CXCR4) antagonist, is the first drug to gain FDA approval for warts, hypogammaglobulinemia, infections and myelokathexis (WHIM) syndrome.